# Safe and Efficient Extracorporeal Photopheresis in Patients with Pre-Procedure Hematocrit below 26%

## TL;DR

This study shows that a medical treatment called extracorporeal photopheresis can be safely used in patients with low blood cell levels, potentially avoiding the need for blood transfusions.

## Contribution

The study demonstrates that extracorporeal photopheresis can be safely performed at lower hematocrit levels than previously recommended.

## Key findings

- ECP procedures at hematocrit below 26% were completed safely without adverse events.
- Procedure duration was not significantly affected by lower hematocrit levels.
- Current hematocrit thresholds for ECP may be overly restrictive.

## Abstract

Extracorporeal photopheresis (ECP) is widely used for graft-versus-host disease (GVHD), but manufacturer recommendations suggest maintaining a pre-procedure hematocrit (Hct) above 27%. This study evaluates the safety and efficacy of ECP performed at lower Hct levels.

We retrospectively analyzed 13 ECP procedures in three male patients with GVHD, comparing sessions performed at Hct < 26% to those at Hct > 27%. Procedural parameters, hemodynamic stability, and adverse events were assessed.

All procedures at Hct < 26% were successfully completed without adverse reactions, vascular access issues, or significant hemodynamic changes. Average procedure duration was 97 min at Hct < 26% and 95 min at Hct > 27%, showing no significant impact on efficiency.

ECP at Hct < 26% is safe and effective, reducing the need for transfusion while maintaining procedural integrity. These findings challenge current Hct thresholds and support more flexible patient selection criteria.